Baxter Posts Q1 2025 Financial Performance
Baxter International Reports First-Quarter 2025 Results, Driven by Strategic Focus and Solid Operational Execution Baxter International Inc. (NYSE: BAX), a global leader in medical technology, today announced its financial results for the first quarter of 2025. The results reflect continued…
Cencora Foundation Event Tackles Inequities in Healthcare Access
Cencora Impact Foundation Conference Champions Global Collaboration to Dismantle Barriers to Healthcare Access The Cencora Impact Foundation, a philanthropic arm of Cencora and an independent not-for-profit charitable organization, recently hosted its sixth annual Nonprofit Partner Conference, reinforcing its deep commitment…
Oklahoma Complete Health Unveils Enhanced 2025 Benefits for SoonerSelect Members
Oklahoma Complete Health Unveils New and Expanded SoonerSelect Benefits to Improve Member Health and Well-Being in 2025 Oklahoma Complete Health is introducing a comprehensive set of new and upgraded benefits for its SoonerSelect members in 2025, continuing its mission to…
Genmab to File sBLA with FDA for Epcoritamab in Combination with R2 Regimen for Relapsed/Refractory Follicular Lymphoma
Genmab to Submit sBLA to FDA for Epcoritamab in Combination with Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma Genmab A/S (Nasdaq: GMAB) has announced its plan to submit a supplemental Biologics License Application (sBLA) to the U.S. Food…
InnoCare Advances as Zurletrectinib Gets Priority Review by China’s NMPA
InnoCare’s Next-Generation TRK Inhibitor Zurletrectinib Granted Priority Review by China’s NMPA for NTRK Fusion-Positive Tumors A prominent biopharmaceutical company dedicated to the development of innovative therapies for cancer and autoimmune diseases, announced a major regulatory milestone today. The Center for…
2025 Clinical Trials Outlook: Key Insights on Trial Launches and Forecasts
2025 Clinical Trials Outlook: Key Trends in Planned Initiations and Projected Completions A Preview of Trials Planned to Initiate and Estimated to Complete, offering a detailed look into the anticipated global clinical trial landscape for the coming year. Drawing on…
CareDx Posts First Quarter 2025 Results Highlighting Key Financial Metrics
CareDx Posts Strong Q1 2025 Results, Driven by Revenue Growth and Strategic Advancements CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on transplant patient care, has reported financial results for the first quarter ended March 31, 2025. The…
Glaukos Reports Q1 2025 Financial Results
Glaukos Corporation Reports Strong First Quarter 2025 Financial Results, Driven by Record Glaucoma Sales and Sustained Pipeline Progress Glaukos Corporation (NYSE: GKOS), a leading ophthalmic pharmaceutical and medical technology company focused on the development and commercialization of novel therapies for…
ICON Releases Q1 2025 Performance Report
ICON Reports First Quarter 2025 Financial Results ICON plc (NASDAQ: ICLR), a leading global clinical research organization (CRO) driven by healthcare intelligence, today announced its financial results for the first quarter of 2025, which ended on March 31, 2025. CEO…
WEX Inc. Announces First Quarter 2025 Financial Results
WEX Inc. (NYSE: WEX), a leading global commerce platform that simplifies the business of running a business, today announced its financial results for the first quarter ended March 31, 2025. Despite a modest revenue decline, the company highlighted solid progress…
Adicet Bio Issues Equity Awards in Accordance with Nasdaq Inducement Rule
Adicet Bio Issues Equity Awards to New Employees Pursuant to Nasdaq Inducement Rule 5635(c)(4) Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company advancing gamma delta T cell therapies for cancer, announced that it has granted equity awards to newly hired…
BIOQUAL Announces Retirement of President and CEO Dr. Mark G. Lewis
BIOQUAL Announces Retirement of President and CEO Dr. Mark G. Lewis; Dr. Hanne Andersen Elyard Named as Successor BIOQUAL, Inc., a leading provider of in vivo and in vitro preclinical research services, has announced the upcoming retirement of its long-serving…